Although only a phase 1b dose-finding study in patients with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL), all but one patient treated with a subcutaneous formulation of the bispecific T-cell engager (BiTE) blinatumomab (Blincyto, Amgen) achieved a complete hematologic response, with no minimal residual disease (MRD), according to interim data presented at the 2021 annual meeting of the American Society of Hematology.
“The study demonstrated